Tuesday, December 5, 2023
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Biopharmaceutical Consultant
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University
Palo Alto, California
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
This activity is intended for an identified target audience of rheumatologists, primary care physicians, and obstetricians/gynecologists.
The goal of this activity is to increase clinicians' competence and confidence in managing patients with moderate to severe rheumatoid arthritis (RA).
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
Biopharmaceutical Consultant
Adjunct Clinical Professor
Division of Immunology and Rheumatology
Stanford University
Palo Alto, California
None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.
Medscape, LLC designates this enduring material for a maximum of 1.25
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC Released: 10/20/2021
Valid for credit through: 10/20/2022, 11:59 PM EST
processing....
 |
Anna is a 26-year-old graduate student who presents to her primary care physician after a 1-month history of morning stiffness in the joints of her fingers, particularly in her dominant hand. The stiffness usually lasts a few hours and is accompanied by polyarticular pain and swelling. She reports some fatigue but no other symptoms and has no significant medical or family history. She does not smoke or drink alcohol. Laboratory studies are significant for an erythrocyte sedimentation rate (ESR) of 40 mm/h (normal range, 0-20 mm/h), C-reactive protein (CRP) of 5 mg/dL (normal range, 0.08-3.1 mg/dL), and positivity for rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA). Ultrasonography shows inflammation in both hands. In her dominant hand, there is significant synovitis (swelling and tenderness) across her proximal interphalangeal (PIP) joints, her metacarpophalangeal (MCP) joints, and in her carpal bones and wrist. The findings are similar in her nondominant hand, but the inflammation is not quite as severe. X-ray also shows well-defined bony erosions in the carpal bones and metacarpal bases. Based on these findings, a diagnosis of rheumatoid arthritis (RA) is made. She is started on oral methotrexate, 15 mg weekly, as well as 2 capsules of celecoxib 200 mg daily.
